In February 2007, health products giant Johnson & Johnson disclosed that some of its foreign units might have made improper payments related to the sale of medical devices. By voluntarily disclosing the information to the Justice Department and the Securities and Exchange Commission, pledging full cooperation with the agency investigations, and accepting the early retirement of the executive responsible for the business units involved, the company may face lighter penalties and limit damage to its reputation. And that’s the good news.
The bad news is that even a company with a longstanding reputation for ethical conduct and responsible behavior can get mixed up in the bribery and corruption maze. Because of its reputation and strong response, Johnson & Johnson may be able to weather this storm. And that should serve as a reminder to every organization involved in international commerce that, along with legal, financial... To get the full story, subscribe now.
Join the Community
Full, instant access
Single-user subscription, one year | $1,199.00
For multi-user subscriptions, call (888) 519-9200